Dalia Rotstein, MD, MPH, assistant professor of medicine at the University of Toronto, lists barriers to multiple sclerosis (MS) research and care delivery.
Dalia Rotstein, MD, MPH, assistant professor of medicine at the University of Toronto, lists barriers to multiple sclerosis (MS) research and care delivery.
The topic was discussed on February 29 at the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum 2024 during the session Rotstein cochaired titled "MS Across Populations and Access to Care."
Transcript
What specific barriers are there to equitable MS research and care delivery?
I think we are facing many barriers today to equitable MS care and also to research. Firstly, I think we have to consider different social determinants of health, and, as highlighted in this session, access to neurologic care is also a key factor.
So, social determinants of health include factors like income, sex, age, race, and ethnicity; also, what the built environment looks like. So, what does the neighborhood that a person lives in look like in terms of access to medical centers, availability of nutritious food, and community support; are they in a situation with social isolation?
All of these factors are very important when we're considering equity goals. I think that, as we saw in recent research that was highlighted by [Marisa McGinley, DO, of Cleveland Clinic], there are many disparities. We observed disparities and access to neurologic care across rural and urban communities in the United States and also across different racial and ethnic communities. The Hispanic and Black communities have lower access to specialized neurologic care, especially MS neurologists.
We need to think about creative solutions for approaching that. I think it's important to engage those different communities and try to find out how we can deliver care in a more accessible manner. Also, there were some novel solutions proposed, such as using telemedicine, for example, to reach people in a more convenient way. I think there are a lot of promising avenues for the future, but there's a lot of work that needs to be done.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More